Cargando…

Differences in risk for type 1 and type 2 ovarian cancer in a large cancer screening trial

OBJECTIVE: To investigate the role of previous gynecologic surgery, hormone use, and use of non-steroidal anti-inflammatory drugs on the risk of type 1 and type 2 ovarian cancer. METHODS: We utilized data collected for the Prostate, Lung, Colorectal, and Ovarian cancer screening trial. All diagnosed...

Descripción completa

Detalles Bibliográficos
Autores principales: Terada, Keith Y., Ahn, Hyeong Jun, Kessel, Bruce
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4823356/
https://www.ncbi.nlm.nih.gov/pubmed/27029746
http://dx.doi.org/10.3802/jgo.2016.27.e25
_version_ 1782425898924900352
author Terada, Keith Y.
Ahn, Hyeong Jun
Kessel, Bruce
author_facet Terada, Keith Y.
Ahn, Hyeong Jun
Kessel, Bruce
author_sort Terada, Keith Y.
collection PubMed
description OBJECTIVE: To investigate the role of previous gynecologic surgery, hormone use, and use of non-steroidal anti-inflammatory drugs on the risk of type 1 and type 2 ovarian cancer. METHODS: We utilized data collected for the Prostate, Lung, Colorectal, and Ovarian cancer screening trial. All diagnosed ovarian cancers were divided into three groups: type 1, endometrioid, clear cell, mucinous, low grade serous, and low grade adenocarcinoma/not otherwise specified (NOS); type 2, high grade serous, undifferentiated, carcinosarcoma, and high grade adenocarcinoma/NOS; and other: adenocarcinoma with grade or histology not specified, borderline tumors, granulosa cell tumors. The odds ratios for type 1, type 2, and other ovarian cancers were assessed with regard to historical information for specific risk factors. RESULTS: Ibuprofen use was associated with a decrease in risk for type 1 ovarian cancer. Tubal ligation and oral contraceptive use were associated with a decrease in risk for type 2 ovarian cancer. A history of ectopic pregnancy was associated with a decreased risk for all ovarian cancers by almost 70%. CONCLUSION: These findings support the hypothesis that carcinogenic pathways for type 1 and type 2 ovarian cancer are different and distinct. The marked reduction in all ovarian cancer risk noted with a history of ectopic pregnancy and salpingectomy implies that the fallopian tube plays a key role in carcinogenesis for both type 1 and type 2 ovarian cancer.
format Online
Article
Text
id pubmed-4823356
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology
record_format MEDLINE/PubMed
spelling pubmed-48233562016-05-01 Differences in risk for type 1 and type 2 ovarian cancer in a large cancer screening trial Terada, Keith Y. Ahn, Hyeong Jun Kessel, Bruce J Gynecol Oncol Original Article OBJECTIVE: To investigate the role of previous gynecologic surgery, hormone use, and use of non-steroidal anti-inflammatory drugs on the risk of type 1 and type 2 ovarian cancer. METHODS: We utilized data collected for the Prostate, Lung, Colorectal, and Ovarian cancer screening trial. All diagnosed ovarian cancers were divided into three groups: type 1, endometrioid, clear cell, mucinous, low grade serous, and low grade adenocarcinoma/not otherwise specified (NOS); type 2, high grade serous, undifferentiated, carcinosarcoma, and high grade adenocarcinoma/NOS; and other: adenocarcinoma with grade or histology not specified, borderline tumors, granulosa cell tumors. The odds ratios for type 1, type 2, and other ovarian cancers were assessed with regard to historical information for specific risk factors. RESULTS: Ibuprofen use was associated with a decrease in risk for type 1 ovarian cancer. Tubal ligation and oral contraceptive use were associated with a decrease in risk for type 2 ovarian cancer. A history of ectopic pregnancy was associated with a decreased risk for all ovarian cancers by almost 70%. CONCLUSION: These findings support the hypothesis that carcinogenic pathways for type 1 and type 2 ovarian cancer are different and distinct. The marked reduction in all ovarian cancer risk noted with a history of ectopic pregnancy and salpingectomy implies that the fallopian tube plays a key role in carcinogenesis for both type 1 and type 2 ovarian cancer. Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology 2016-05 2015-12-31 /pmc/articles/PMC4823356/ /pubmed/27029746 http://dx.doi.org/10.3802/jgo.2016.27.e25 Text en Copyright © 2016. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Terada, Keith Y.
Ahn, Hyeong Jun
Kessel, Bruce
Differences in risk for type 1 and type 2 ovarian cancer in a large cancer screening trial
title Differences in risk for type 1 and type 2 ovarian cancer in a large cancer screening trial
title_full Differences in risk for type 1 and type 2 ovarian cancer in a large cancer screening trial
title_fullStr Differences in risk for type 1 and type 2 ovarian cancer in a large cancer screening trial
title_full_unstemmed Differences in risk for type 1 and type 2 ovarian cancer in a large cancer screening trial
title_short Differences in risk for type 1 and type 2 ovarian cancer in a large cancer screening trial
title_sort differences in risk for type 1 and type 2 ovarian cancer in a large cancer screening trial
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4823356/
https://www.ncbi.nlm.nih.gov/pubmed/27029746
http://dx.doi.org/10.3802/jgo.2016.27.e25
work_keys_str_mv AT teradakeithy differencesinriskfortype1andtype2ovariancancerinalargecancerscreeningtrial
AT ahnhyeongjun differencesinriskfortype1andtype2ovariancancerinalargecancerscreeningtrial
AT kesselbruce differencesinriskfortype1andtype2ovariancancerinalargecancerscreeningtrial